Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

Search Again »

Abstract Number: 2962 • 2014 ACR/ARHP Annual Meeting
Association of the Toll-like Receptor 4 (TLR4) Gene with Gout
Humaira Rasheed¹, Ruth Topless¹, Richard Day², Diluk Kannangara³, Kenneth Williams³, Linda Bradbury⁴, Matthew Brown⁵, Catherine Hill⁶, Susan Lester⁷, Maureen Rischmueller⁸, Malcolm Smith⁹, Mariano Andrés¹⁰, Thomas Bardin¹¹, Michael Doherty¹², Matthijs Janssen¹³, Tim Jansen¹⁴, Leo Joosten¹⁵, Fernando Perez-Ruiz¹⁶, Timothy Radstake¹⁷, Philip L. Riches¹⁸, Ed Roddy¹⁹, Anne-Kathrin Tausche²⁰, Lisa K. Stamp²¹, Nicola Dalbeth²², Frederic Lioté²³, Alex So²⁴, Cushla McKinney¹ and Tony R. Merriman¹, ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²Dept of Clin Pharmacology, St. Vincent's Hospital, Sydney, Australia, ³University of New South Wales, Sydney, Australia, ⁴The University of Queensland, Brisbane, Australia, ⁵University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Queen Elizabeth Hospital, Adelaide, Australia, ⁷Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia, ⁸Department of Rheumatology, The Queen Elizabeth Hospital, SA, Australia, ⁹Rheumatology Unit Repatriation, Queen Elizabeth Hospital, Adelaide, Australia, ¹⁰Rheumatology Section, Hospital General Universitario de Alicante, Alicante, Spain, ¹¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ¹²Academic Rheumatology, City Hospital, Nottingham, United Kingdom, ¹³Department of Rheumatology, Rijnstate Hospital, Arnhem, Netherlands, ¹⁴Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ¹⁵Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ¹⁶Servicio de Reumatologia, Hospital De Cruces, Baracaldo, Spain, ¹⁷University Medical Center Utrecht, Utrecht, Netherlands, ¹⁸Centre for Rheumatic Diseases, University of Edinburgh, Edinburgh, United Kingdom, ¹⁹Research Institute for Primary Care and Health Sciences, Keele University, Staffordshire, United Kingdom, ²⁰Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ²¹University of Otago, Christchurch, New Zealand, ²²Department of Medicine, University of Auckland, Auckland, New Zealand, ²³UFR médicale, Université Paris Diderot, Paris, France, ²⁴Service De Rhumatologie, CHUV, Lausanne, Switzerland
Background/Purpose: Gout results from innate immune response to monosodium urate (MSU) crystals that form in the context of supersaturation of urate. Identification of genetic risk…
Abstract Number: 2963 • 2014 ACR/ARHP Annual Meeting
The URAT1 Uric Acid Transporter Is Important in Uric Acid Homeostasis and Its Activity May be Altered in Gout Patients and in Drug-Induced Hyperuricemia
Philip K. Tan, Sha Liu and Jeffrey N. Miner, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout results from chronic hyperuricemia. Most gout patients exhibit an increased renal reabsorption of uric acid which leads to elevated levels of serum uric…
Abstract Number: 2964 • 2014 ACR/ARHP Annual Meeting
Association Analysis of Apolipoprotein B and Very Low-Density Lipoprotein with Hyperuricemia and Gout
Humaira Rasheed¹, Angela Hsu¹, Nicola Dalbeth², Lisa K. Stamp³, Sally McCormick¹ and Tony R. Merriman¹, ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Otago, Christchurch, New Zealand
Background/Purpose: Gout results from an innate immune response to monosodium urate (MSU) crystals deposited in joints. Increased very low-density lipoprotein (VLDL) has been associated with…
Abstract Number: 2322 • 2014 ACR/ARHP Annual Meeting
Aim for Better Gout Control: A Retrospective Analysis of Preventable Hospital Admissions for Gout
Tarun S. Sharma¹, Thomas M. Harrington² and Thomas P. Olenginski², ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Dept of Rheumatology, Geisinger Health System, Danville, PA
Background/Purpose: ACR/EULAR guidelines have been published on the management of gout. Despite these guidelines, many patients with gout suffer recurrent flares and hospitalizations resulting in…
Abstract Number: 2179 • 2014 ACR/ARHP Annual Meeting
The Monocyte-Phagocyte System in Gout: Enhanced Inflammasome Activity and Expansion of CD14++CD16+ Monocytes in Patients with Gout
Emma Garcia-Melchor¹, Cesar Diaz-Torne², Monica Guma^3,4, Europa Azucena Gonzalez-Navarro⁵, Francesc Xavier Alemany⁶, Jordi Yagüe¹ and Manel Juan¹, ¹Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain, ²Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ⁴Rheumatology, UCSD School of Medicine, La Jolla, CA, ⁵Immunology, Hospital Clinic Barcelona, Barcelona, Spain, ⁶Emergency, Hospital Clinic Barcelona, Barcelona, Spain
Background/Purpose: The central role of the monocyte-macrophage system in gout has been highlighted during the last years. Macrophages initiate the inflammatory response to monosodium urate…
Abstract Number: 2148 • 2014 ACR/ARHP Annual Meeting
Dual Energy CT Scanning: Variable Sensitivity for Gout in Non-Tophaceous and Tophaceous Disease and in Individual Erosions
Tracie Kurano¹, Uma Thakur², Gaurav Thawait³, Elliot Fishman⁴, Mara McAdams-DeMarco⁵, Janet W. Maynard⁶, Matthew Fuld⁷, John A. Carrino⁸ and Alan N. Baer⁹, ¹Medicine-Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Musculoskeletal Radiology Section, Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, ³Musculoskeletal Radiology Section, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Research Collaborations - Computed Tomography R&D, Siemens Medical Solutions USA, Inc., Baltimore, MD, ⁸Radiology, Hospital for Special Surgery, New York, NY, ⁹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dual energy computed tomography (DECT) is emerging as a diagnostic tool for gout, but its sensitivity has not been established. We assessed the sensitivity…
Abstract Number: 2114 • 2014 ACR/ARHP Annual Meeting
Comorbidity Characteristics of Patients Starting First-Line Acute Gout Agents – Colchicine, NSAID, and Corticosteroids
Alfonso Perez¹, Robert Jackson², Jiao Yang³, Aki Shiozawa⁴, Shawn Yu⁴, Yimin Qin¹, Huifang Liang⁵ and Hyon K. Choi⁶, ¹Global Clinical Science, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ²Global Medical Office, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ³Analytical Science, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ⁴Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ⁵Pharmacovigilance, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ⁶Boston University School of Medicine, Boston, MA
Comorbidity Characteristics of Patients Starting First-Line Acute Gout Agents - Colchicine, NSAID, and CorticosteroidsBackground/Purpose: There is a remarkable, increasing disease burden of gout and its…
Abstract Number: 2121 • 2014 ACR/ARHP Annual Meeting
Real-World Cost Comparison of Urate Lowering Therapies in Patients with Gout and Moderate to Severe Chronic Kidney Disease
Ghaith Mitri¹, Eric Wittbrodt¹, Robin Turpin¹, Beni Tidwell² and Kathy Schulman², ¹Medical Affairs, Takeda Pharmaceuticals International, Deerfield, IL, ²Outcomes Research Solutions, Inc., Waltham, MA
Background/Purpose Gout flare prevention relies heavily on urate-lowering therapies (ULT) such as allopurinol (ALP) and febuxostat (FBX) but clinical decision-making in patients with moderate to…
Abstract Number: 2125 • 2014 ACR/ARHP Annual Meeting
Burden of Illness in Refractory Gouty Arthritis: A One-Year Prospective Multinational, Observational Study
Louis Bessette¹, Frédéric Lioté², Carmen Moragues³, Rüdiger Moericke⁴, Zhang Zhiyi⁵, Alberto Ferreira⁶, Pascal Lecomte⁶, Sophia Kessabi⁶, Haijun Tian⁷ and Jasvinder A. Singh^8,9, ¹CHUL, Quebec, QC, Canada, ²Hôpital Lariboisière & University Paris Diderot, Paris, France, ³Hospital Platón, Barcelona, Italy, ⁴Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ⁵The First Affiliated Hospital of Haerbin Medical University, Haerbin, China, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Mayo Clinic, Rochester, MN, ⁹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Refractory gouty arthritis (RGA) is a condition characterized by appearance of recurrent flares and contraindication, intolerance, or lack of efficacy to first-line anti-inflammatory therapy…
Abstract Number: 2003 • 2014 ACR/ARHP Annual Meeting
Pilot Study of a Web-Based Module on Gout
Bernadette Siaton¹, Elizabeth Clayton², Alexandra Kueider³ and Matthew Rietschel⁴, ¹Rheumatology, University of Maryland Medical System, Baltimore, MD, ²Division of Rheumatology, University of Maryland, Baltimore, MD, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴University of Maryland School of Nursing, Baltimore, MD
Background/Purpose: The majority of internal medicine trainees complete residency with little exposure to rheumatology. We aimed to create a validated, self-directed, web-based, core curriculum in…
Abstract Number: 1874 • 2014 ACR/ARHP Annual Meeting
Obesity Paradox in Recurrent Gout – a Metrological Clarification and Remedy
Uyen Sa D.T. Nguyen^1,2, Qiong Louie-Gao³, Yuqing Zhang⁴, David T. Felson³, Michael P. Lavalley⁵ and Hyon K. Choi⁶, ¹Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ²Clinical Epidemiology Research &Training Unit, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Biostatistics, Boston University, Boston, MA, ⁶Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Obesity is a strong risk factor of incident gout, but previous research showed no such association with recurrent gout among gout patients. These paradoxical…
Abstract Number: 1873 • 2014 ACR/ARHP Annual Meeting
Food Sources of Protein and Risk of Incident Gout in the Singapore Chinese Health Study
Gim Gee Teng^1,2, An Pan³, Jian-Min Yuan⁴ and Woon-Puay Koh^3,5, ¹Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore, ²Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ³Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, ⁴Division of Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute, and Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁵Duke-NUS Graduate Medical School Singapore, Singapore, Singapore

Background/Purpose: The Health Professional Follow up Study in Caucasian men showed that intakes of meat and seafood increased risk of gout, while dairy products, especially…
Abstract Number: 1872 • 2014 ACR/ARHP Annual Meeting
Gout in Older Adult
Mara McAdams-DeMarco¹, Anna Kottgen², Bridget Burke³, Andrew Law⁴, Josef Coresh¹ and Alan N. Baer⁵, ¹Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Renal Division, University Hospital Freiburg, Freiburg, Germany, ³Johns Hopkins University, Baltimore, MD, ⁴Epidemiology, Johns Hopkins, Baltimore, MD, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: To evaluate whether traditional and genetic risk factors in middle-aged members of a longitudinal population-based cohort predict the onset of gout in older age.…
Abstract Number: 1808 • 2014 ACR/ARHP Annual Meeting
Role of HLA-B*5801 Genetic Testing and a Safety Programme When Initiating Allopurinol Therapy for Chronic Gout Management: A Cost-Effectiveness Analysis
Di Dong¹, Wei Chuen Tan-Koi^2,3, Gim Gee Teng^4,5, Eric Finkelstein⁶ and Cynthia Sung^7,8, ¹Health Services and Systems Research Program, Duke-NUS Graduate Medical School, Singapore, Singapore, ²Vigilance & Compliance Branch, Health Sciences Authority, Singapore, Singapore, Singapore, ³Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, ⁴Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁵Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore, ⁶Health Services and Systems Research Program, Duke-NUS Graduate Medical School, Singapore., Singapore, Singapore, ⁷Vigilance & Compliance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore, Singapore, Singapore, ⁸Emerging Infectious Diseases Program, Duke-NUS Graduate Medical School, Singapore., Singapore, Singapore
Background/Purpose To conduct a cost-effectiveness analysis from a health system perspective of various strategies in managing chronic gout to mitigate risk of allopurinol-induced Stevens-Johnson Syndrome…
Abstract Number: 1221 • 2014 ACR/ARHP Annual Meeting
Serum Uric Acid As an Independent Risk Factor on Progression of Chronic Kidney Disease in Gout Patients with Uric Acid Lowering Agent
Young Hyup Lim¹, Eun-Jung Park¹, Seulkee Lee², Hemin Jeong³, Hyungjin Kim⁴, Jinseok Kim¹, Jaejoon Lee⁵, Hoon-Suk Cha³ and Eun-Mi Koh⁶, ¹Internal Medicine, Department of Medicine, Jeju National University Hospital, Jeju University School of Medicine, Republic of Korea, Jeju, South Korea, ²Internal Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, Seoul, South Korea, ³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Internal Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, Seul, South Korea, ⁵Division of Rheumatology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁶Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose Hyperuricemia is particularly common in patients with chronic kidney disease (CKD). Its role, however, as a risk factor for renal outcomes of CKD is…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].